Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00608920 · ClinicalTrials.gov registry record · NA

Single Photon Emission Computed Tomography (SPECT) Lymph Node Mapping

A NA study of Adenocarcinoma of the Prostate, sponsored by Washington University School of Medicine.

Completed
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT00608920 is a NA study of Adenocarcinoma of the Prostate that has completed, run by Washington University School of Medicine. The registered enrollment target is 15 participants, below the 109-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00608920, a NA study of Adenocarcinoma of the Prostate, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if the planning of radiation treatment of prostate cancer patient can be made more precise by comparing currently planning techniques to an imaging technique called SPECT.

Interventions

  • OTHER Single Photon Emission Computed Tomography (SPECT)

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2007-03
Est. Completion 2009-04
Phase NA

What the Registry Record Tells You About NCT00608920

The ClinicalTrials.gov registry entry for NCT00608920 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (86% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Adenocarcinoma of the Prostate appearing as the primary indexed condition, and to 1 intervention - of which Single Photon Emission Computed Tomography (SPECT) is the first listed.

NCT00608920 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT00608920 about?

NCT00608920 is a clinical study titled "Single Photon Emission Computed Tomography (SPECT) Lymph Node Mapping". The purpose of this study is to determine if the planning of radiation treatment of prostate cancer patient can be made more precise by comparing currently planning techniques to an imaging technique called SPECT.

What is the current status of trial NCT00608920?

This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2007-03. Estimated completion is 2009-04.

What conditions does trial NCT00608920 study?

This clinical trial studies the following conditions: Adenocarcinoma of the Prostate.

What interventions are being tested in trial NCT00608920?

The interventions under investigation include: Single Photon Emission Computed Tomography (SPECT) (OTHER).

Who is sponsoring clinical trial NCT00608920?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00608920 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Adenocarcinoma of the Prostate

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.